AU2003244398A1 - Engineering absorption of therapeutic compounds via colonic transporters - Google Patents

Engineering absorption of therapeutic compounds via colonic transporters

Info

Publication number
AU2003244398A1
AU2003244398A1 AU2003244398A AU2003244398A AU2003244398A1 AU 2003244398 A1 AU2003244398 A1 AU 2003244398A1 AU 2003244398 A AU2003244398 A AU 2003244398A AU 2003244398 A AU2003244398 A AU 2003244398A AU 2003244398 A1 AU2003244398 A1 AU 2003244398A1
Authority
AU
Australia
Prior art keywords
transporters
therapeutic compounds
compounds via
engineering
absorption
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003244398A
Other languages
English (en)
Inventor
Kenneth C. Cundy
Mark A. Gallop
Noa Zerangue
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
XenoPort Inc
Original Assignee
XenoPort Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by XenoPort Inc filed Critical XenoPort Inc
Publication of AU2003244398A1 publication Critical patent/AU2003244398A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2003244398A 2002-01-24 2003-01-24 Engineering absorption of therapeutic compounds via colonic transporters Abandoned AU2003244398A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US35180802P 2002-01-24 2002-01-24
US60/351,808 2002-01-24
US10/351,291 2003-01-23
US10/351,291 US20030158254A1 (en) 2002-01-24 2003-01-23 Engineering absorption of therapeutic compounds via colonic transporters
PCT/US2003/002206 WO2003065982A2 (en) 2002-01-24 2003-01-24 Engineering absorption of therapeutic compounds via colonic transporters

Publications (1)

Publication Number Publication Date
AU2003244398A1 true AU2003244398A1 (en) 2003-09-02

Family

ID=27737413

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003244398A Abandoned AU2003244398A1 (en) 2002-01-24 2003-01-24 Engineering absorption of therapeutic compounds via colonic transporters

Country Status (7)

Country Link
US (1) US20030158254A1 (https=)
EP (1) EP1575494A2 (https=)
JP (1) JP2005529847A (https=)
KR (1) KR20040111348A (https=)
AU (1) AU2003244398A1 (https=)
CA (1) CA2473802A1 (https=)
WO (1) WO2003065982A2 (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
CA2449729C (en) * 2001-06-11 2009-11-03 Xenoport, Inc. Prodrugs of gaba analogs, compositions and uses thereof
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
UA78529C2 (en) 2001-10-10 2007-04-10 Wyeth Corp Derivatives of [[2-(amino-3,4-dioxo-1-cyclobutene-1-yl)amino]alkyl] acid for treating pain
US7378239B2 (en) * 2002-06-25 2008-05-27 Index Diagnostics Ab Method of differentiating between ulcerative colitis and Crohn's disease
US7025745B2 (en) * 2002-10-07 2006-04-11 Advanced Cardiovascular Systems, Inc. Method of making a catheter balloon using a tapered mandrel
WO2005098444A2 (en) * 2003-07-03 2005-10-20 Xenoport, Inc. Monocarboxylate transporters expressed in cancer cells
JP2007509155A (ja) * 2003-10-21 2007-04-12 アルファーマ インコーポレイテッド クエチアピンを含有する薬剤
KR20060108692A (ko) * 2003-10-31 2006-10-18 알자 코포레이션 메트포르민의 개선된 흡수를 위한 조성물 및 제형
WO2005074996A2 (en) * 2004-01-30 2005-08-18 Xenoport, Inc. Lat1 transporter expressed in blood brain barrier cells
US7452680B2 (en) * 2004-01-30 2008-11-18 Xenoport, Inc. MCT1 transporters expressed in blood brain barrier cells
WO2005117998A2 (en) * 2004-06-04 2005-12-15 Xenoport, Inc. Smvt transporters expressed in cancer cells
WO2005121070A1 (en) * 2004-06-04 2005-12-22 Xenoport, Inc. Levodopa prodrugs, and compositions and uses thereof
PT1751087E (pt) * 2004-06-04 2012-09-10 Xenoport Inc Derivados de levodopa e as suas composições e utilizações
WO2005121787A2 (en) * 2004-06-04 2005-12-22 Xenoport, Inc. Lat1 transporters expressed in cancer cells
US20060003362A1 (en) * 2004-06-04 2006-01-05 Xenoport, Inc. ENT1 transporters expressed in cancer cells
WO2006001986A2 (en) * 2004-06-04 2006-01-05 Xenoport, Inc. Glut3 transporters expressed in cancer cells
US7348276B2 (en) * 2005-03-30 2008-03-25 Fujitsu, Limited Fabrication process of semiconductor device and polishing method
KR20080005429A (ko) * 2005-04-19 2008-01-11 알자 코포레이션 트라마돌 및 가바펜틴을 포함하는 물질의 배합물
ZA200711123B (en) * 2005-06-27 2009-08-26 Biovail Lab Int Srl Modified-release formulations of a bupropion salt
US7563821B2 (en) * 2005-12-05 2009-07-21 Xenoport, Inc. Levodopa prodrug mesylate, compositions thereof, and uses thereof
WO2008052044A2 (en) * 2006-10-26 2008-05-02 Xenoport, Inc. Use of derivatives of propofol for treating diseases associated with oxidative stress
WO2008079387A1 (en) * 2006-12-21 2008-07-03 Xenoport, Inc. Catechol protected levodopa diester prodrugs, compositions, and methods of use
CA2673336A1 (en) 2006-12-21 2008-06-26 Xenoport, Inc. Levodopa dimethyl-substituted diester prodrugs, compositions, and methods of use
US8828665B2 (en) 2007-02-16 2014-09-09 Ark Diagnostics, Inc. Compounds and methods for use in detecting gabapentin
WO2009033069A1 (en) * 2007-09-07 2009-03-12 Xenoport, Inc. Simple pantoic acid ester neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use
TW200932734A (en) * 2007-10-15 2009-08-01 Xenoport Inc Internally masked neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use
DK2223121T3 (da) * 2007-12-20 2012-10-22 Index Diagnostics Ab Publ Fremgangsmåde og kit til anvendelse ved differentiering mellem ibd og ibs og yderligere skelnen mellem ibd-sygdomstyper
US8399513B2 (en) * 2008-10-20 2013-03-19 Xenoport, Inc. Levodopa prodrug mesylate hydrate
US9290445B2 (en) * 2008-10-20 2016-03-22 Xenoport, Inc. Methods of synthesizing a levodopa ester prodrug
WO2010048423A1 (en) 2008-10-24 2010-04-29 Ark Diagnostics, Inc. Levetiracetam immunoassays
WO2011056240A2 (en) 2009-11-09 2011-05-12 Xenoport, Inc. Pharmaceutical compositions and oral dosage forms of a levodopa prodrug and methods of use
EP2945942B1 (en) 2013-01-18 2018-05-09 ARK Diagnostics, Inc. Voriconazole immunoassays
EP2956444B1 (en) 2013-02-13 2018-05-30 ARK Diagnostics, Inc. Posaconazole immunoassays
BR112022026837A2 (pt) * 2020-07-01 2023-01-24 Capsugel Belgium Nv Composição e método dietético

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2504010B1 (fr) * 1981-04-15 1985-10-25 Sanofi Sa Medicaments anticancereux contenant la chaine a de la ricine associee a un anticorps antimelanome et procede pour leur preparation
US4671958A (en) * 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US4542225A (en) * 1984-08-29 1985-09-17 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
US4590071A (en) * 1984-09-25 1986-05-20 Xoma Corporation Human melanoma specific immunotoxins
US4659839A (en) * 1984-10-10 1987-04-21 Mallinckrodt, Inc. Coupling agents for radiolabeled antibody fragments
US4680338A (en) * 1985-10-17 1987-07-14 Immunomedics, Inc. Bifunctional linker
US4699784A (en) * 1986-02-25 1987-10-13 Center For Molecular Medicine & Immunology Tumoricidal methotrexate-antibody conjugate
US5563250A (en) * 1987-12-02 1996-10-08 Neorx Corporation Cleavable conjugates for the delivery and release of agents in native form
US4904474A (en) * 1988-01-25 1990-02-27 Alza Corporation Delivery of drug to colon by oral disage form
IT1251153B (it) * 1991-08-06 1995-05-04 Vectorpharma Int Composizioni farmaceutiche solide per somministrazione orale aventi proungata residenza gastrica
ZA953078B (en) * 1994-04-28 1996-01-05 Alza Corp Effective therapy for epilepsies
CA2269806C (en) * 1996-10-28 2006-01-24 Bernhard H. Van Lengerich Embedding and encapsulation of controlled release particles
IL119890A (en) * 1996-12-24 2002-03-10 Teva Pharma Gabapentin form iii and preparation of gabapentin form ii
US6652864B1 (en) * 1998-12-21 2003-11-25 Asilomar Pharmaceuticals, Inc. Compounds for intracellular delivery of therapeutic moieties to nerve cells

Also Published As

Publication number Publication date
WO2003065982A3 (en) 2005-12-08
WO2003065982A2 (en) 2003-08-14
CA2473802A1 (en) 2003-08-14
EP1575494A2 (en) 2005-09-21
KR20040111348A (ko) 2004-12-31
JP2005529847A (ja) 2005-10-06
US20030158254A1 (en) 2003-08-21

Similar Documents

Publication Publication Date Title
AU2003244398A1 (en) Engineering absorption of therapeutic compounds via colonic transporters
AU2003244650A8 (en) Medicinal compounds
GB0225540D0 (en) Medicinal compounds
GB0204719D0 (en) Medicinal compounds
GB0225535D0 (en) Medicinal compounds
GB0220730D0 (en) Medicinal compounds
GB0225030D0 (en) Medicinal compounds
AU2003290734A1 (en) Novel compounds as pharmaceutical agents
EP1551426A4 (en) PROCESS FOR THE ADMINISTRATION OF FGF18
AU2003234929A1 (en) Therapeutic agent for diabetes
AU2003294318A1 (en) Therapeutic bioconjugates
AU2003251904A1 (en) Combinations of drugs for the treatment of neoplasms
AU2003251875A1 (en) Combination therapy for the treatment of neoplasms
AU2002353739A1 (en) Therapeutic compounds
AU2003215150A1 (en) Therapeutic compounds
AU2003211586A1 (en) Drugs containing riboflavin-type compounds
AU2003224000A1 (en) Compounds useful as photodynamic therapeutic agents
AU2003296385A1 (en) Therapeutic single dose gas administration system
GB0208392D0 (en) Therapeutic compounds
AU2003213349A1 (en) Therapeutic agent for pain
AU2002950182A0 (en) Compounds for medicinal purposes
HK1080458A (en) Benzimidazol-1-yl-thiophene compounds for the treatment of cancer
GB0200134D0 (en) Therapeutic compounds
GB0200135D0 (en) Therapeutic Compounds
GB0200136D0 (en) Therapeutic compounds

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase